Frenkel Ran

Average Profitability
<0.0001%
Insider Buys Quantity
2
Insider Buys Sum
$190,860.00
Insider Sells Quantity
9
Insider Sells Sum
$413,335.83

Insider Activity of Frenkel Ran

The largest purchase of all time was on 2015-04-07 and amounted to 4000 shares of Karyopharm Therapeutics Inc. for $132,000.

The largest sale of all time was on 2017-11-07 and amounted to 9916 shares of Karyopharm Therapeutics Inc. for $111,510.

Biography of Frenkel Ran

No biography is available at this moment.

2022-02-28SaleKaryopharm Therapeutics Inc.
KPTI
EVP, Chief Dev. Officer
1,663
0.0021%
$10.24$17,025-51.02%
2022-02-17SaleKaryopharm Therapeutics Inc.
KPTI
EVP, Chief Dev. Officer
2,929
0.0038%
$12.12$35,509-57.42%
2022-02-07SaleKaryopharm Therapeutics Inc.
KPTI
EVP, Chief Dev. Officer
1,991
0.0025%
$9.86$19,635-49.61%
2021-02-18SaleKaryopharm Therapeutics Inc.
KPTI
EVP, Chief Dev. Officer
2,887
0.0039%
$14.83$42,818-42.84%
2021-02-11SaleKaryopharm Therapeutics Inc.
KPTI
EVP, Chief Dev. Officer
2,046
0.0028%
$15.52$31,752-45.02%
2020-05-07SaleKaryopharm Therapeutics Inc.
KPTI
Chief Dev Operations Officer
1,974
0.0028%
$20.00$39,480-21.53%
2020-02-19SaleKaryopharm Therapeutics Inc.
KPTI
Chief Dev Operations Officer
2,975
0.0044%
$16.48$49,034-0.43%
2017-11-07SaleKaryopharm Therapeutics Inc.
KPTI
Chief Dev Operations Officer
9,916
0.0209%
$11.25$111,510+38.14%
2016-11-14SaleKaryopharm Therapeutics Inc.
KPTI
Chief Dev Operations Officer
6,618
0.0176%
$10.06$66,572+0.3%
2015-04-07PurchaseKaryopharm Therapeutics Inc.
KPTI
EVP, WW Development Operations
4,000
0.0118%
$33.00$132,000-54.71%
2015-04-06PurchaseKaryopharm Therapeutics Inc.
KPTI
EVP, WW Development Operations
2,000
0.0055%
$29.43$58,860-52.41%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.